Heidelberg Pharma Reports Outcome Of Annual General Meeting

Ladenburg, Germany, 21 May 2019 - Heidelberg Pharma AG (FSE: WL6) today announced that the shareholders of the Company approved the resolutions of the administration with large majorities (ranged from 99.81% to 100%) during the Annual General Meeting today. The members of the Executive Management Board and the Supervisory Board were formally approved and Deloitte GmbH Wirtschaftsprüfungsgesellschaft was appointed as auditors and group auditors for the financial year 2018/2019. At the Annual General Meeting 2019, 80.35% of the current share capital were represented.

Dr. Jan Schmidt-Brand, Chief Executive Officer and Chief Financial Officer of Heidelberg Pharma AG, commented: "We have achieved important milestones with our own Antibody-Amanitin-Conjugates (ATAC) in the fiscal year 2018 and the last few months, generated interesting new data and seen good progress with the product candidates of our licensing partners. Our business is developing positively in line with our planning. We are now on the target line of an extensive preclinical development program and complex manufacturing process for our first ATAC candidate and aim to treat the first Multiple Myeloma patient in 2020. On behalf of the Management Board, I would like to thank the shareholders of Heidelberg Pharma AG for their confidence in and support of our company."

Please find more information here: http://heidelberg-pharma.com/en/press-and-investors/annual-general-meeting.

About Heidelberg Pharma

Heidelberg Pharma AG is a biopharmaceutical company based in Ladenburg, Germany. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company's proprietary therapeutic ATACs, as well as in third-party collaborations, to create a variety of ATAC candidates. The proprietary lead candidate is HDP-101, a BCMA ATAC for multiple myeloma.

The Company has entered into partnerships to further develop and commercialize its clinical assets MESUPRON(R) and REDECTANE(R). Heidelberg Pharma AG is listed on the Frankfurt Stock Exchange: ISIN DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available atwww.heidelberg-pharma.com.

Heidelberg Pharma AG
Corporate Communications
Sylvia Wimmer
Tel.: +49 89 41 31 38-29
E-Mail: investors[at]hdpharma.com
Schriesheimer Str. 101, 68526 Ladenburg

IR/PR support
MC Services AG
Katja Arnold (CIRO)
Managing Director & Partner
Tel.: +49 89 210 228-40
Mobil: +49 160 9360 3022
E-Mail: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to the Company's business, which can be identified by the use of forward-looking terminology such as "estimates", "believes", "expects", "may", "will" "should" "future", "potential" or similar expressions or by a general discussion of the Company's strategy, plans or intentions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.

Back to news